IRIDEX CORP (IRIX) SEC Filings

IRIDEX CORP (IRIX) reported that its Chief Financial Officer, Romeo R. Dizon, purchased 2,354 shares of common stock on September 14, 2026 at $0.65 per share in an open-market or private transaction. Following this buy, he directly holds 177,406 shares of IRIDEX common stock. No Rule 10b5-1 trading plan is reported for this transaction.

IRIDEX CORP (IRIX) reported that Chief Financial Officer Romeo R. Dizon purchased 5,100 shares of common stock on September 10, 2026 at $0.68 per share in an open-market or private transaction. Following this purchase, he directly holds 175,052 shares of IRIDEX common stock. No Rule 10b5-1 trading plan is reported for this transaction.

IRIDEX Corporation (IRIX) reports that Nasdaq has notified it of non-compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, after the stock traded below that level for the last 30 consecutive business days.

Under Nasdaq Listing Rule 5810(c)(3)(A), IRIDEX has a 180-day Cure Period to February 23, 2027 to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it meets other Nasdaq initial listing standards (apart from bid price) and commits to cure the deficiency, including potentially via a reverse stock split, it may receive an additional 180 days. If compliance is not regained, the common stock may be delisted, subject to an appeal process. The company states that the notice has no immediate impact on trading, business operations, or SEC reporting and that it is monitoring its stock price and evaluating options.

IRIDEX CORP (IRIX) reported that Chief Financial Officer Romeo R. Dizon purchased shares of the company’s Common Stock. On 2026-08-24, he bought 1,300 shares at $0.7488 per share and 5,368 shares at $0.7499 per share in open-market or private transactions. Following these purchases, his reported direct ownership increased to 169,952 Common Stock shares.

IRIDEX Corporation (IRIX) reported lower revenue but a smaller net loss for the three and six months ended July 4, 2026. Quarterly revenue was $12.6 million, down 7.4% year over year, with Cyclo G6 glaucoma products growing while retina product revenue declined. Gross margin was 34.2%, slightly below 34.5% a year earlier, as higher manufacturing and tariff-related costs weighed on profitability. The company posted a quarterly net loss of $1.3 million (–$0.07 per share), compared with a $1.0 million loss in the prior-year quarter; year-to-date loss improved to $1.8 million from $2.7 million.

Cash and cash equivalents were $4.7 million with working capital of $10.8 million, against total liabilities of $23.6 million, including a $3.8 million convertible note. Deferred revenue totaled $8.2 million, largely from a 10‑year exclusive distribution arrangement with Topcon, which accounted for about 30–33% of revenue. Management highlights ongoing cost-control initiatives, a continued shift to lower-cost contract manufacturers, and macroeconomic and geopolitical uncertainty affecting capital equipment demand.

IRIDEX CORP (IRIX) reported second quarter 2026 revenue of $12.6 million, down 7% from $13.6 million a year earlier, as weaker retina sales offset growth in glaucoma products. Retina product revenue fell to $6.5 million from $8.0 million, while Cyclo G6 product family revenue rose 19% to $3.9 million, driven by higher probe volumes.

Gross margin was stable at 34.2% versus 34.5% last year. Operating expenses declined 5% to $5.3 million on lower general and administrative costs, but net loss widened to $1.3 million (–$0.07 per share) from $1.0 million (–$0.06). Adjusted EBITDA moved to a loss of $0.4 million from a small profit. The company was operating cash-flow positive in the quarter and ended July 4, 2026 with $4.7 million in cash and cash equivalents.

IRIDEX reaffirmed full-year 2026 revenue guidance of $51–$53 million and expects fiscal 2026 adjusted operating expenses of $19.0–$19.5 million. Management highlighted ongoing cost-transformation efforts, including shifting production to lower-cost contract manufacturers and relocating headquarters, which are intended to support long-term profitability.

Mercer Patrick reported acquisition or exercise transactions in this Form 4 filing.

IRIDEX CORP President and CEO Patrick Mercer received equity awards on July 10, 2026, including 100,000 restricted stock units, 100,000 performance RSUs that vest if the share price reaches $2.50 for 30 consecutive trading days, and options for 200,000 shares at $1.10 per share. The RSUs and options vest as to one-third of the shares on July 10, 2027 and on each one-year anniversary thereafter, subject to continued service. Following these awards he directly holds 468,784 common shares, plus 100,000 performance units and 200,000 options.

IRIDEX CORP awarded its Chief Financial Officer, Romeo R. Dizon, equity-based compensation consisting of 30,000 restricted stock units (RSUs) and a stock option for 170,000 shares. Each RSU represents a contingent right to receive one share of common stock, vesting in three equal annual installments: one-third on July 10, 2027 and one-third on each of the next two anniversaries, subject to his continued service.

The option gives Dizon the right to purchase up to 170,000 shares of IRIDEX common stock at an exercise price of $1.10 per share and expires on July 10, 2033. Following these awards, he holds 163,284 shares of common stock directly, in addition to the newly granted stock option. These are compensation grants rather than open‑market purchases or sales.